Exelixis (EXEL) Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EXEL shares.
View EXEL analyst ratings or view top-rated stocks.

8 equities research analysts have issued 1 year target prices for Exelixis' stock. Their EXEL share price forecasts range from $20.00 to $32.00. On average, they expect the company's stock price to reach $25.33 in the next twelve months. This suggests a possible upside of 33.3% from the stock's current price.
View analysts price targets for EXEL or view top-rated stocks among Wall Street analysts.

Exelixis' stock was trading at $16.04 at the beginning of the year. Since then, EXEL stock has increased by 18.5% and is now trading at $19.01.
View the best growth stocks for 2023 here.

Exelixis saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 7,410,000 shares, an increase of 21.5% from the April 30th total of 6,100,000 shares. Based on an average trading volume of 3,050,000 shares, the days-to-cover ratio is currently 2.4 days.
View Exelixis' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our EXEL earnings forecast.

Exelixis, Inc. (NASDAQ:EXEL) announced its earnings results on Tuesday, February, 7th. The biotechnology company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by $0.04. The biotechnology company had revenue of $423.92 million for the quarter, compared to the consensus estimate of $418.71 million. Exelixis had a trailing twelve-month return on equity of 6.20% and a net margin of 9.24%. The company's quarterly revenue was down 6.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.29 EPS.

ETFs with the largest weight of Exelixis (NASDAQ:EXEL) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Dynamic Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), First Trust Health Care AlphaDEX Fund (FXH), ERShares Entrepreneurs ETF (ENTR), IQ U.S. Mid Cap R&D Leaders ETF (MRND) and Invesco S&P MidCap Quality ETF (XMHQ).

Exelixis issued an update on its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.77 billion-$1.88 billion, compared to the consensus revenue estimate of $1.83 billion.

75 employees have rated Exelixis Chief Executive Officer Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among the company's employees. 38.0% of employees surveyed would recommend working at Exelixis to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Exelixis' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.14%), Farallon Capital Management LLC (7.22%), Renaissance Technologies LLC (4.70%), State Street Corp (3.98%), JPMorgan Chase & Co. (2.38%) and Price T Rowe Associates Inc. MD (1.85%). Insiders that own company stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, Dana Aftab, George Poste, Gisela Schwab, Jack L Wyszomierski, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Patrick J Haley, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi.
View institutional ownership trends.

Shares of EXEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EXEL stock can currently be purchased for approximately $19.01.

Exelixis (NASDAQ:EXEL) has a market capitalization of $6.19 billion and generates $1.61 billion in revenue each year. The biotechnology company earns $182.28 million in net income (profit) each year or $0.48 on an earnings per share basis.

The company employs 1,223 workers across the globe.

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The official website for the company is www.exelixis.com. The biotechnology company can be reached via phone at (650) 837-7000, via email at shubbard@exelixis.com, or via fax at 650-837-8300.